Resolution of exudative changes refractory to ranibizumab after aflibercept injections at the margin of inferior staphyloma in tilted disc syndrome

Ophthalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):384-6. doi: 10.3928/23258160-20150323-16.

Abstract

An 81-year-old woman presented with blurred vision in the left eye. Best corrected visual acuity was 20/100. Ophthalmologic examination in the left eye revealed tilted disc syndrome with exudative change at the margin of inferior staphyloma. The exudative change persisted despite monthly intravitreal ranibizumab injections for 5 months. Subsequently, two intravitreal aflibercept injections 1 month apart were substituted for the ranibizumab injections, resulting in successful resolution of the exudative change.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Coloring Agents
  • Drug Substitution
  • Epiretinal Membrane / diagnosis
  • Epiretinal Membrane / drug therapy
  • Eye Abnormalities / diagnosis
  • Eye Abnormalities / drug therapy*
  • Female
  • Fluorescein Angiography
  • Humans
  • Indocyanine Green
  • Intravitreal Injections
  • Macular Edema / diagnosis
  • Macular Edema / drug therapy
  • Optic Disk / abnormalities*
  • Ranibizumab
  • Receptors, Vascular Endothelial Growth Factor / therapeutic use*
  • Recombinant Fusion Proteins / therapeutic use*
  • Retinal Detachment / diagnosis
  • Retinal Detachment / drug therapy
  • Retinal Diseases / diagnosis
  • Retinal Diseases / drug therapy*
  • Retinal Pigment Epithelium / drug effects
  • Retinal Pigment Epithelium / pathology
  • Subretinal Fluid / drug effects*
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Coloring Agents
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor
  • Indocyanine Green
  • Ranibizumab